These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 30043207

  • 21. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy.
    Liu F, Du Y, Cai B, Yan M, Yang W, Wang Q.
    J Cancer Res Ther; 2017; 13(5):790-795. PubMed ID: 29237905
    [Abstract] [Full Text] [Related]

  • 22. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
    Zhang JY, Liu YX, Wang H, Mi L, Song GH, Jiang HF, Yan Y, Shao B, Kong WY, Zhang RY, Ran R, Liu XR, Wang J, Lin YT, Li HP.
    Zhonghua Yi Xue Za Zhi; 2018 Sep 11; 98(34):2718-2721. PubMed ID: 30220167
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z, Grecea D, Smakal M, Tjulandin S, Bondarenko I, Perjesi L, Illes A, Horvat-Karajz K, Aradi I.
    BMC Cancer; 2019 Feb 06; 19(1):122. PubMed ID: 30727980
    [Abstract] [Full Text] [Related]

  • 24. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.
    Sun XS, Wang Z, Ren SH, Zhang HL, Liu LJ, Du HB, Liu XW, Liu JF.
    Thorac Cancer; 2022 Sep 06; 13(17):2429-2435. PubMed ID: 35859328
    [Abstract] [Full Text] [Related]

  • 25. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH.
    Support Care Cancer; 2017 Feb 06; 25(2):505-511. PubMed ID: 27709313
    [Abstract] [Full Text] [Related]

  • 26. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
    Shi YK, Feng FY, Sun Y.
    Zhonghua Nei Ke Za Zhi; 1994 Nov 06; 33(11):739-42. PubMed ID: 7541325
    [Abstract] [Full Text] [Related]

  • 27. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
    Huang HQ, Bai B, Gao YH, Zou DH, Zou SH, Tan H, Song YP, Li ZY, Jin J, Li W, Su H, Gong YP, Zhong MZ, Shuang YR, Zhu J, Zhang JQ, Cai Z, Teng QL, Sun WJ, Yang Y, Xia ZJ, Chen HL, Hua LM, Bao YY, Wu N.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct 14; 38(10):825-830. PubMed ID: 29166732
    [Abstract] [Full Text] [Related]

  • 28. [Comparative study on the efficacy and safety between pegfilgrastim (PEG-rhG-CSF) and recombinant human granulocyte colony-stimulating factor in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation after hematological malignancy].
    Yang F, Sun XD, Yuan L, Zhang JC, Hu JW, Liu N, Lou X, Su YF, Yu ZY, Chen JL, Li YH, Hu LD, Chen H, Jiang M.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct 14; 38(10):831-836. PubMed ID: 29166733
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics and safety of pegylated recombinant human granulocyte colony-stimulating factor in children with acute leukaemia.
    Liu XT, Zhao YX, Jia GW, Yang F, Zhang CZ, Han B, Dai JH, Han YQ, Tang BH, Yang XM, Shi HY, Zhou Y, Sui ZG, Chen JZ, van den Anker JN, Zhao W.
    Br J Clin Pharmacol; 2021 Aug 14; 87(8):3292-3300. PubMed ID: 33506975
    [Abstract] [Full Text] [Related]

  • 30. [Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial].
    Yang WY, Liu TF, Chen XJ, Guo Y, Li T, Qi BQ, Liu F, Chang LX, Ruan M, Liu XM, Zhang L, Zou Y, Chen YM, Zhu XF.
    Zhongguo Dang Dai Er Ke Za Zhi; 2020 Nov 14; 22(11):1172-1177. PubMed ID: 33172550
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
    Liu C, Hao Y, Wang L, Meng F, Wen F, Zhong D.
    Thorac Cancer; 2021 Apr 14; 12(8):1154-1161. PubMed ID: 33590721
    [Abstract] [Full Text] [Related]

  • 32. Treatment of chemotherapy-induced neutropenia in children with subcutaneously administered recombinant human granulocyte colony-stimulating factor.
    Okamura J, Yokoyama M, Tsukimoto I, Komiyama A, Sakurai M, Imashuku S, Miyazaki S, Ueda K, Hanawa Y, Takaku F.
    Pediatr Hematol Oncol; 1992 Apr 14; 9(3):199-207. PubMed ID: 1381941
    [Abstract] [Full Text] [Related]

  • 33. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
    Wang C, Zhu S, Miao C, Wang Y, Chen J, Yuan S, Hu X.
    BMC Cancer; 2022 May 13; 22(1):542. PubMed ID: 35562713
    [Abstract] [Full Text] [Related]

  • 34. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW, Moon YW, Mezei K, Láng I, Bhat G, Chawla S, Hasal SJ, Schwartzberg LS.
    Cancer Med; 2020 Sep 13; 9(17):6234-6243. PubMed ID: 32687266
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats.
    Tanaka H, Satake-Ishikawa R, Ishikawa M, Matsuki S, Asano K.
    Cancer Res; 1991 Jul 15; 51(14):3710-4. PubMed ID: 1712246
    [Abstract] [Full Text] [Related]

  • 36. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
    Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DY, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ.
    Anticancer Drugs; 2013 Jul 15; 24(6):641-7. PubMed ID: 23571496
    [Abstract] [Full Text] [Related]

  • 37. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
    Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA.
    Support Care Cancer; 2016 Apr 15; 24(4):1709-17. PubMed ID: 26423618
    [Abstract] [Full Text] [Related]

  • 38. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
    Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.
    Ann Oncol; 2002 Jun 15; 13(6):903-9. PubMed ID: 12123336
    [Abstract] [Full Text] [Related]

  • 39. Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.
    Tian W, Wang Y, Zhou Y, Yao Y, Deng Y.
    Front Oncol; 2022 Jun 15; 12():777602. PubMed ID: 35547875
    [Abstract] [Full Text] [Related]

  • 40. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.
    Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L.
    N Engl J Med; 1988 Jun 02; 318(22):1414-22. PubMed ID: 2452983
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.